公开(公告)号：US11254987B2

公开(公告)日：2022-02-22

申请号：US15821407

申请日：2017-11-22

Applicant: Genentech, Inc.

Inventor： Edward Kadel ,  Marcin Kowanetz ,  Kimberly Walter

IPC: C07K16/28 ,  C12Q1/6886 ,  A61P35/00

Abstract: This invention provides methods for the treatment of cancer in subjects having medium or low methylation level in the PD-L1 promoter region. Also provided are related kits and articles of manufacture.

公开(公告)号：US20180363066A1

公开(公告)日：2018-12-20

申请号：US16115373

申请日：2018-08-28

Applicant: Foundation Medicine, Inc. ,  Genentech, Inc.

Inventor： Zachary R. Chalmers ,  Caitlin F. Connelly ,  David Fabrizio ,  Garrett Michael Frampton ,  Priti Hegde ,  Marcin Kowanetz ,  Philip J. Stephens ,  James Xin Sun ,  Roman Yelensky

IPC: C12Q1/6886 ,  C12Q1/6806 ,  C12Q1/6827

Abstract: Methods of evaluating tumor mutational burden in a sample, e.g., a tumor sample or a sample derived from a tumor, from a subject, are disclosed.

公开(公告)号：US20250052759A1

公开(公告)日：2025-02-13

申请号：US18933358

申请日：2024-10-31

Applicant: Genentech, Inc.

Inventor： Marcin Kowanetz ,  Daniel Shin-Yu Chen ,  Hartmut Koeppen

IPC: G01N33/574 ,  A61K39/00 ,  A61K39/395 ,  A61K45/06 ,  C07K16/28 ,  C07K16/30 ,  C12Q1/6886 ,  G06Q30/0241 ,  G06Q30/0251

Abstract: Provided herein are biomarkers for the treatment of pathological conditions, such as cancer, and method of using PD-1/PD-L1 pathway antagonists. In particular, provided are biomarkers for patient selection and prognosis in cancer, as well as methods of therapeutic treatment, articles of manufacture and methods for making them, diagnostic kits, methods of detection and methods of advertising related thereto.

公开(公告)号：US11300570B2

公开(公告)日：2022-04-12

申请号：US16371589

申请日：2019-04-01

Applicant: Genentech, Inc. ,  Foundation Medicine, Inc.

Inventor： David Fabrizio ,  Garrett M. Frampton ,  Priti Hegde ,  Marcin Kowanetz ,  David Shames ,  Philip J. Stephens ,  James Xin Sun ,  Roman Yelensky ,  Wei Zou

IPC: G01N33/574 ,  C07K16/28 ,  C12Q1/6886 ,  A61P35/04 ,  A61P35/00 ,  A61K38/17 ,  A61K39/395 ,  A61K45/06 ,  C07K14/705 ,  A61K39/00

Abstract: The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma. The invention provides methods of treating cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma), methods of determining whether a patient suffering from cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma) is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma) to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma), based on a tissue tumor mutational burden (tTMB) score, which reflects somatic mutation levels of genes in a tumor tissue sample obtained from the patient, alone or in combination with PD-L1 expression levels (e.g., PD-L1 expression levels in tumor or tumor-infiltrating immune cells in a tumor sample (tumor area) obtained from the patient).

公开(公告)号：US20190219586A1

公开(公告)日：2019-07-18

申请号：US16371589

申请日：2019-04-01

Applicant: Genentech, Inc. ,  Foundation Medicine, Inc.

Inventor： David Fabrizio ,  Garrett M. Frampton ,  Priti Hegde ,  Marcin Kowanetz ,  David Shames ,  Philip J. Stephens ,  James Xin Sun ,  Roman Yelensky ,  Wei Zou

IPC: G01N33/574 ,  A61P35/00 ,  C07K16/28 ,  C07K14/705 ,  A61K45/06 ,  C12Q1/6886 ,  A61K39/395 ,  A61K38/17 ,  A61P35/04

CPC classification number: G01N33/57492 ,  A61K38/1774 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/55 ,  A61P35/00 ,  A61P35/04 ,  C07K14/70532 ,  C07K16/2827 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/76 ,  C07K2319/30 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/156 ,  G01N2333/70596 ,  G01N2800/52

Abstract: The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma. The invention provides methods of treating cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma), methods of determining whether a patient suffering from cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma) is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma) to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma), based on a tissue tumor mutational burden (tTMB) score, which reflects somatic mutation levels of genes in a tumor tissue sample obtained from the patient, alone or in combination with PD-L1 expression levels (e.g., PD-L1 expression levels in tumor or tumor-infiltrating immune cells in a tumor sample (tumor area) obtained from the patient).

公开(公告)号：US11535671B2

公开(公告)日：2022-12-27

申请号：US16655495

申请日：2019-10-17

Applicant: Genentech, Inc.

Inventor： Priti Hegde ,  Marcin Kowanetz ,  Gregg Fine ,  Sanjeev Mariathasan ,  Richard Bourgon

IPC: C07K16/28 ,  C12Q1/6886 ,  G01N33/574 ,  A61K39/00

Abstract: The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, bladder cancer. The invention provides methods of treating bladder cancer, methods of determining whether a patient suffering from bladder cancer is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from bladder cancer to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from bladder cancer, based on expression levels of a biomarker of the invention (e.g., PD-L1 expression levels in tumor-infiltrating immune cells in a tumor sample obtained from the patient) and/or based on the determination of a tumor sample subtype.

公开(公告)号：US11299544B2

公开(公告)日：2022-04-12

申请号：US14850462

申请日：2015-09-10

Applicant: Genentech, Inc.

Inventor： Daniel Shin-Yu Chen ,  Priti Hegde ,  Hartmut Koeppen ,  Marcin Kowanetz

IPC: G01N33/574 ,  A61K39/00 ,  C07K16/28 ,  C12Q1/6886 ,  G01N33/68 ,  G06Q30/02

Abstract: Provided herein are biomarkers for the treatment of pathological conditions, such as cancer, and method of using PD-1/PD-L1 pathway antagonists. In particular, provided are biomarkers for patient selection and prognosis in cancer, as well as methods of therapeutic treatment, articles of manufacture and methods for making them, diagnostic kits, methods of detection and methods of advertising related thereto.